Toronto, Ontario – February 4, 2008 – AIM Therapeutics Inc. (“AIM”) is pleased to announce that the company’s asthma program has entered the next phase of development towards the clinic.  Based on positive results from recent efficacy and dose-response studies, AIM has initiated the pre-clinical development program for its lead Neutropel candidate, AIM-102, for the treatment of asthma.   

AIM has engaged CARBOGEN AMCIS AG for process development and cGMP manufacture of AIM-102, with plans to complete its pre-clinical development program for the treatment of asthma by the end of the third quarter of 2008. 

AIM is a privately held pharmaceutical company focused on developing novel medical treatments for inflammatory and immune disorders.  The company’s most advanced program is a breakthrough technology called Neutropel, which is a non-toxic, non-steroidal therapeutic that can be given orally, by inhalation or by injection.  

“The potential for AIM-102 to effectively treat asthma without steroid-like side effects will significantly improve the lives of many people who suffer from this debilitating disease” said Dr. Richard Timmer, AIM President and CEO.  “We are proud of our progress, and we look forward to working with CARBOGEN AMCIS AG to advance the development of our asthma program.” 

AIM will work closely with CARBOGEN AMCIS AG to develop and manufacture cGMP material.  The cGMP material will be used to support the pre-clinical development program, as well as Phase I clinical studies for AIM’s asthma program.  AIM has chosen to work with CARBOGEN AMCIS AGE because of their excellent track record, attention to detail, and strong capabilities in both process development and cGMP manufacturing for the pharmaceutical industry. 

For more information about AIM Therapeutics and any of its technologies or development programs, please visit www.aimtherapeutics.com. 

About AIM Therapeutics AIM Therapeutics Inc. is a privately held biotechnology company focused on the development of peptide-based therapeutic candidates for the treatment of asthma, cardiovascular disease, diabetes, spinal cord injury, and other inflammatory and immune disorders.  The Company’s therapeutic candidates are based on research from leading scientists at the University of Western Ontario and the University of Calgary.  AIM Therapeutics is pursuing the pre-clinical validation and development of its lead candidates through a virtual business model being managed by BioQuest Innovations Inc.   

About CARBOGEN AMCIS AGCARBOGEN AMCIS AG is a leading service provider, offering a portfolio of drug-development and commercialization services to the pharmaceutical and biopharmaceutical industry at all stages of drug development. The integrated services provide innovative chemistry solutions to support timely and safe drug development allowing customers to make the best use of available resources.